Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2021 16:19 ET | Source: Chimerix, Inc.

Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock

DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
January 08, 2021 06:00 ET | Source: Chimerix, Inc.

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential...
January 06, 2021 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference

DURHAM, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
December 07, 2020 07:00 ET | Source: Chimerix, Inc.

Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

DURHAM, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
November 05, 2020 16:01 ET | Source: Chimerix, Inc.

Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference

DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
November 05, 2020 07:00 ET | Source: Chimerix, Inc.

Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update

– Completed Rolling NDA Submissions for Both BCV Tablet and Suspension Formulations as Medical Countermeasure for Smallpox – – First Patient Visit for DSTAT Phase 3 AML Study Expected in Early...
October 29, 2020 07:00 ET | Source: Chimerix, Inc.

Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020

DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
September 10, 2020 08:00 ET | Source: Chimerix, Inc.

Chimerix to Participate in Upcoming Investor Conferences

DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
August 10, 2020 07:00 ET | Source: Chimerix, Inc.

Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update

– Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 – – Currently Enrolling Phase 2/3 Study of DSTAT in Patients with COVID-19; Phase 2 Enrollment Completion Expected in Fourth...
August 03, 2020 08:00 ET | Source: Chimerix, Inc.

Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...